Comparative Pharmacology
Head-to-head clinical analysis: DORMATE versus DOXY SLEEP AID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORMATE versus DOXY SLEEP AID.
DORMATE vs DOXY-SLEEP-AID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gamma-aminobutyric acid (GABA) type A receptor positive allosteric modulator; increases chloride ion influx, enhancing inhibitory neurotransmission.
Doxy-Sleep-Aid is a sedative-hypnotic drug that acts as a positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA. It selectively binds to α1 subunits of GABA-A receptors, promoting sleep onset and maintenance.
10 mg orally once daily at bedtime, not to exceed 10 mg/day.
Doxylamine succinate 25 mg orally once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life 8-12 hours in healthy adults; prolonged in renal impairment (up to 30 hours) and elderly.
10-12 hours; extended in elderly and hepatic impairment
Primarily renal excretion (60-80% as unchanged drug and metabolites); biliary/fecal excretion accounts for 15-25%.
Renal: 40% unchanged; biliary/fecal: 60% as metabolites
Category C
Category C
Antihistamine (Sedating)
Antihistamine (Sedating)